Insulet | PODD - Cost Of Sales


Insulet reported $215.2M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 4.92B 535M Dec/2025
Align Technology USD 363.97M 7.48M Dec/2025
AtriCure USD 35.16M 2.23M Dec/2025
Avanos Medical USD 94.9M 3.1M Dec/2025
Baxter International USD 2.4B 512M Dec/2025
Becton, Dickinson and Co. USD 2.84B 2.35B Dec/2025
Boston Scientific USD 1.84B 82M Dec/2025
Cardinal Health USD 63.36B 1.57B Dec/2025
Cooper Companies USD 464.2M 45.9M Sep/2025
Dexcom USD 466.9M 11M Dec/2025
Edwards Lifesciences USD 343M 2.2M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Globus Medical USD 282.38M 3.42M Sep/2025
ICU Medical USD 337.72M 1.61M Dec/2025
Inogen USD 39.59M 1.27M Sep/2024
Insulet USD 215.2M 19M Dec/2025
Integra LifeSciences USD 193.44M 1.62M Dec/2025
J&J USD 7.97B 689M Dec/2025
Masimo USD 140.9M 3.3M Sep/2025
Medtronic USD 3.61B 83M Dec/2025
Merit Medical Systems USD 198.58M 838K Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Solventum Corp USD 971M 8M Dec/2025
Stryker USD 2.69B 373M Dec/2025
Tandem Diabetes Care USD 122.92M 7.96M Dec/2025
Teleflex USD 261.54M 199.84M Dec/2025
West Pharmaceutical Services USD 501.1M 9.2M Dec/2025
Zimmer Biomet Holdings USD 970.1M 234.3M Dec/2025